Allogene Therapeutics, Inc. (ALLO)

3,0700 +0,1000 (+3,37%) Börsenschluss: 04:00PM EDT

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 232

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Arie S. Belldegrun F.A.C.S., M.D.	Co-Founder & Executive Chairman	649,1k	N/A	1949
Dr. David D. Chang M.D., Ph.D.	Co-Founder, President, CEO & Director	994,6k	N/A	1960
Mr. Joshua A. Kazam	Co-Founder & Director	260,5k	N/A	1977
Mr. Timothy L. Moore Ph.D.	Executive VP & Chief Technical Officer	554,35k	N/A	1961
Dr. Zachary J. Roberts M.D., Ph.D.	Executive VP of Research & Development and Chief Medical Officer	747,39k	N/A	1978
Mr. Geoffrey M. Parker	Executive VP & CFO	N/A	N/A	1965
Mr. Earl M. Douglas Esq.	Senior VP, General Counsel, Compliance Officer & Corporate Secretary	N/A	N/A	1963
Ms. Susan R. Lundeen	Chief People Officer	N/A	N/A	1966
Ms. Christine Cassiano	Executive VP, Chief Corporate Affairs & Brand Strategy Officer	N/A	N/A	N/A
Yinlin Chen	Senior Vice President of Finance	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Allogene Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.